Rick--only the GLFD PD trial you already know about, that will complete in 2005. The only other mention of neuroimmunophilins came in a JPET article in May (Murray et al, from Lilly), where they ran a number of erstwhile neuroprotective/regenerative compounds (including neuroimmunophilins) through two PD models. Their conclusion, which was surprising to me, was that the most robust regenerative effects came from their allosteric AMPA modulators (their version of Cortex's Ampakines). Thus, at least in that run through the 6OHDA and MPTP models, neuroimmunophilins (and nitric synthase inhibitors, antioxidants, nicotine, antiinflammatories) did not perform as well as the Lilly AMPA-modulator.
My ardor for neuroimmunophilins is not what it was in 1996. I'll be interested to see the GLFD Phase II data, but I am not expecting it to be nearly as groundbreaking as neuroimmunophilins once appeared to be.
Regards,
Harry
NeuroInvestment |
